The surveillance inspection, conducted from March 10 to March 14, 2025, concluded without any observations. On Thursday (March 13), shares of Zydus Lifesciences Ltd ended at ₹883.05, down by ₹5.95, or 0.67%, on the BSE.
Zydus Lifesciences’ API unit in Ankleshwar, Gujarat clears USFDA inspection with nil observations
Share it
